The classic website will no longer be available as of June 25, 2024. Please use the modernized
Working… Menu

Study of EBT-101 in Aviremic HIV-1 Infected Adults on Stable ART

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT05144386
Recruitment Status : Active, not recruiting
First Posted : December 3, 2021
Last Update Posted : May 16, 2024
Information provided by (Responsible Party):
Excision BioTherapeutics

Tracking Information
First Submitted Date  ICMJE November 22, 2021
First Posted Date  ICMJE December 3, 2021
Last Update Posted Date May 16, 2024
Actual Study Start Date  ICMJE January 24, 2022
Estimated Primary Completion Date May 2025   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: November 22, 2021)
Safety and Tolerability of EBT-101 [ Time Frame: 48 weeks ]
Safety and tolerability of EBT-101 will be assessed based on the incidence and severity of adverse events (AEs) according to Division of AIDS (DAIDS) 2017 over 48 weeks
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE Not Provided
Original Secondary Outcome Measures  ICMJE Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE Study of EBT-101 in Aviremic HIV-1 Infected Adults on Stable ART
Official Title  ICMJE A Phase 1/2a, Sequential Cohort, Single Ascending Dose Study of the Safety, Tolerability, Biodistribution, and Pharmacodynamics of EBT 101 in Aviremic HIV-1 Infected Adults on Stable Antiretroviral Therapy
Brief Summary This is a First in Human (FIH) study of EBT-101 administered IV to aviremic HIV-1 infected adults on stable antiretroviral therapy (ART).
Detailed Description

This is a FIH, open-label, sequential cohort, single ascending dose (SAD) study of EBT-101 administered IV to aviremic HIV-1 infected adults on stable ART.

Participants will be asked to attend several visits for screening to determine eligibility. On Day 1, eligible participants will receive a single IV dose of EBT-101. All participants will be assessed for eligibility for an analytical treatment interruption (ATI) of their background ART at Week 12. All participants will be followed through Week 48 (end of study). Participants are required to attend multiple study visits at the clinical site including daily visits for the first 14 days, followed by weekly visits after Week 12 for ATI participants. Non-ATI participants are followed monthly after Week 12.

Eligible participants who are enrolled in the FIH study (EBT-101-001) will also be enrolled in a separate Long Term Follow Up (LTFU) study (EBT-101-002) for safety monitoring. The duration of the LTFU study is 15 years.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE HIV-1-infection
Intervention  ICMJE Biological: EBT-101
EBT-101 is a HIV-1-specific clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 gene editing system delivered by adenovirus-associated virus vector serotype 9 (AAV9) for intravenous (IV) administration
Study Arms  ICMJE
  • Experimental: EBT-101 Dose-Level 1
    Cohort A: Participants will be administered dose-level 1 of EBT-101
    Intervention: Biological: EBT-101
  • Experimental: EBT-101 Dose-Level 2
    Cohort B: Participants will be administered dose-level 2 of EBT-101
    Intervention: Biological: EBT-101
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: May 14, 2024)
Original Estimated Enrollment  ICMJE
 (submitted: November 22, 2021)
Estimated Study Completion Date  ICMJE May 2025
Estimated Primary Completion Date May 2025   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria (abbreviated):

  • Willing to enroll and sign the written informed consent for EBT-101-001 (current study) and EBT-101-002, the LTFU study.
  • Age between 18 and 70 years (both inclusive).
  • Weight: Cohort A ≥55 and ≤110 kg, Cohort B ≥55 and ≤90 kg.
  • Cohorts A and B will only enroll male subjects (sex at birth).
  • Chronic HIV-1 with known subtype B infection
  • On stable regimen defined as continuous ART suppressive treatment with HIV RNA level below the level of quantitation for >1 years prior to screening
  • Plasma HIV-1 RNA levels below the limit of quantitation during screening.
  • Peripheral blood CD4 T cell count ≥500 cells/mm3 for at least 2 years prior to screening
  • Willing and able to comply, as assessed by the Investigator, with all study-related procedures.
  • Have previously been vaccinated for N. meningitidis with documented history and/or received a N. meningitidis vaccination prior to dosing.
  • Willing to stop ART if eligible for analytical treatment interruption.
  • Willing to comply with the measures to prevent HIV transmission and reinfection required by the protocol.
  • Must have received a COVID-19 vaccination series and boosters as specified by current federal (CDC) recommendations, with the last dose ≥30 days prior to dosing.

Exclusion Criteria (abbreviated):

  • Documented prior HIV-1 drug resistance to ≥2 or more classes of ART defined as single key mutations or an accumulation of minor mutations that result in resistance to entire respective drug classes within the past 5 years.
  • History of >1 change in ART due to virologic failure during preceding 2 years prior to screening.
  • Received in the preceding 12 months or HCP plans to prescribe long-acting injectable ART.
  • History of HIV dementia.
  • History of progressive multifocal leukoencephalopathy.
  • History of significant cardiac disease in last 2 years.
  • History of HIV-related kidney disease with abnormal renal function.
  • Known history and/or documented: pre-HIV treatment nadir CD4+ T cell count <200 cells/mm3 or post-suppressive HIV treatment confirmed CD4+ T cell <200 cells/mm3 prior to screening
  • History of AIDS-defining opportunistic infection prior to screening.
  • Evidence of acute or chronic hepatitis B and/or hepatitis C.
  • Known history or diagnosis of liver cirrhosis.
  • Diagnosis of nonalcoholic fatty liver or advanced nonalcoholic steatohepatitis.
  • Predefined abnormal laboratory values within 42 days of dosing per protocol
  • Known history of positive tuberculin skin test.
  • Receipt of any investigational HIV vaccine (prophylactic and/or therapeutic) within the year prior to screening.
  • Receipt of any gene therapy product approved or experimental, at any time.
  • Anti-AAV9 serum neutralizing antibodies (Nabs) >1:20 titer.
  • Known positive SARS-CoV-2 test within 48 hours prior to planned dosing date.
Sex/Gender  ICMJE
Sexes Eligible for Study: Male
Gender Based Eligibility: Yes
Gender Eligibility Description: Cohorts A and B will enroll male adults (sex at birth)
Ages  ICMJE 18 Years to 70 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT05144386
Other Study ID Numbers  ICMJE EBT-101-001
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Current Responsible Party Excision BioTherapeutics
Original Responsible Party Same as current
Current Study Sponsor  ICMJE Excision BioTherapeutics
Original Study Sponsor  ICMJE Same as current
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: William Kennedy, MD Excision BioTherapeutics
PRS Account Excision BioTherapeutics
Verification Date May 2024

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP